Private artificial intelligence firm to help data mine for UK genomics project
- Boston-based, privately held Berg uses artificial intelligence (AI) to discover new drugs and devices.
- Berg and the Genomics England 100,000 Genomes Project are collaborating to accelerate drug and device development.
- Other industry partners in this project include Roche, Biogen, AstraZeneca and GlaxoSmithKline.
Although it may sound very Spielbergian, using A.I. to mine genomics data is a useful way to look at what's going on inside of cells, and conduct detailed studes of proteins, as well as intricate processes such as formation of cell membranes and intercellular communications.
By using a supercomputer platform, Berg's researchers are able to look at data patterns in order to better understand the basic biology underscoring particular diseases. They are also able to attack the area of genomics with the understanding that genes are only one part of what drives disease processes.